Clinical trial
Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate
NCT02649478
Study timeline
Study start (unknown)2014-08-01Date precision: month
Registry last updated2018-01-23
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Asthmaunresolved
Interventions
Fluticasone / SalmeterolDRUG · verified · RxNorm: fluticasone / salmeterol
PlaceboDRUG
Sponsors & collaborators
Roxane Laboratorieslead sponsor
Vectura Limitedcollaborator
Mapped research locations
MiamiFlorida, United States9Los AngelesCalifornia, United States3Huntington BeachCalifornia, United States3New YorkNew York, United States2BaltimoreMaryland, United States2San AntonioTexas, United States2San DiegoCalifornia, United States2OrlandoFlorida, United States2DenverColorado, United States2RichmondVirginia, United States2HialeahFlorida, United States2HoustonTexas, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02649478 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.